Ex Vivo Gene Therapy Using Patient IPSC-derived NSCs Reverses Pathology in the Brain of a Homologous Mouse Model

Overview

Journal Stem Cell Reports

Publisher Cell Press

Specialty Cell Biology

Date 2015 Apr 14

PMID 25866157

Citations 28

Authors

Tagan A Griffin

Hayley C Anderson

John H Wolfe

Affiliations

Soon will be listed here.

Abstract

Neural stem cell (NSC) transplantation is a promising strategy for delivering therapeutic proteins in the brain. We evaluated a complete process of ex vivo gene therapy using human induced pluripotent stem cell (iPSC)-derived NSC transplants in a well-characterized mouse model of a human lysosomal storage disease, Sly disease. Human Sly disease fibroblasts were reprogrammed into iPSCs, differentiated into a stable and expandable population of NSCs, genetically corrected with a transposon vector, and assessed for engraftment in NOD/SCID mice. Following neonatal intraventricular transplantation, the NSCs engraft along the rostrocaudal axis of the CNS primarily within white matter tracts and survive for at least 4 months. Genetically corrected iPSC-NSCs transplanted post-symptomatically into the striatum of adult Sly disease mice reversed neuropathology in a zone surrounding the grafts, while control mock-corrected grafts did not. The results demonstrate the potential for ex vivo gene therapy in the brain using human NSCs from autologous, non-neural tissues.

Citing Articles

Human iPSC-derived neural stem cells engraft and improve pathophysiology of MPS I mice.

Calhoun C, Kan S, Stover A, Harb J, Monuki E, Wang R Mol Ther Methods Clin Dev. 2025; 32(4):101367.

PMID: 39764351 PMC: 11701249. DOI: 10.1016/j.omtm.2024.101367.

Neurological Disease Modeling Using Pluripotent and Multipotent Stem Cells: A Key Step towards Understanding and Treating Mucopolysaccharidoses.

Carvalho S, Santos J, Moreira L, Goncalves M, David H, Matos L Biomedicines. 2023; 11(4).

PMID: 37189853 PMC: 10135551. DOI: 10.3390/biomedicines11041234.

Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II.

Smith M, Belur L, Karlen A, Podetz-Pedersen K, Erlanson O, Laoharawee K Mol Genet Metab. 2023; 138(4):107539.

PMID: 37023503 PMC: 10705040. DOI: 10.1016/j.ymgme.2023.107539.

Gene-modified neural progenitor cells for the treatment of neuropathic lysosomal storage diseases.

Mandolfo O, Bigger B Neural Regen Res. 2023; 18(9):1954-1955.

PMID: 36926718 PMC: 10233779. DOI: 10.4103/1673-5374.367845.

Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders.

Placci M, Giannotti M, Muro S Adv Drug Deliv Rev. 2023; 197:114683.

PMID: 36657645 PMC: 10629597. DOI: 10.1016/j.addr.2022.114683.

References

Tabar V, Panagiotakos G, Greenberg E, Chan B, Sadelain M, Gutin P . Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nat Biotechnol. 2005; 23(5):601-6. DOI: 10.1038/nbt1088. View

Park I, Lerou P, Zhao R, Huo H, Daley G . Generation of human-induced pluripotent stem cells. Nat Protoc. 2008; 3(7):1180-6. DOI: 10.1038/nprot.2008.92. View

Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P . Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab. 2004; 83(1-2):163-74. DOI: 10.1016/j.ymgme.2004.07.003. View

Maciaczyk J, Singec I, Maciaczyk D, Klein A, Nikkhah G . Restricted spontaneous in vitro differentiation and region-specific migration of long-term expanded fetal human neural precursor cells after transplantation into the adult rat brain. Stem Cells Dev. 2009; 18(7):1043-58. DOI: 10.1089/scd.2008.0346. View

Watson D, Kobinger G, Passini M, Wilson J, Wolfe J . Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther. 2002; 5(5 Pt 1):528-37. DOI: 10.1006/mthe.2002.0584. View

Hofling A, Vogler C, Creer M, Sands M . Engraftment of human CD34+ cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage disease. Blood. 2002; 101(5):2054-63. DOI: 10.1182/blood-2002-08-2597. View

Snyder E, Wolfe J . Central nervous system cell transplantation: a novel therapy for storage diseases?. Curr Opin Neurol. 1996; 9(2):126-36. DOI: 10.1097/00019052-199604000-00013. View

Platt F, Boland B, van der Spoel A . The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012; 199(5):723-34. PMC: 3514785. DOI: 10.1083/jcb.201208152. View

Passini M, Watson D, Vite C, Landsburg D, Feigenbaum A, Wolfe J . Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of.... J Virol. 2003; 77(12):7034-40. PMC: 156185. DOI: 10.1128/jvi.77.12.7034-7040.2003. View

10.

Snyder E, Taylor R, Wolfe J . Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature. 1995; 374(6520):367-70. DOI: 10.1038/374367a0. View

11.

Falk A, Koch P, Kesavan J, Takashima Y, Ladewig J, Alexander M . Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons. PLoS One. 2012; 7(1):e29597. PMC: 3260177. DOI: 10.1371/journal.pone.0029597. View

12.

Chan E, Ratanasirintrawoot S, Park I, Manos P, Loh Y, Huo H . Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol. 2009; 27(11):1033-7. DOI: 10.1038/nbt.1580. View

13.

Sommer C, Sommer A, Longmire T, Christodoulou C, Thomas D, Gostissa M . Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells. 2009; 28(1):64-74. PMC: 4848036. DOI: 10.1002/stem.255. View

14.

Guzman R, Uchida N, Bliss T, He D, Christopherson K, Stellwagen D . Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci U S A. 2007; 104(24):10211-6. PMC: 1891235. DOI: 10.1073/pnas.0608519104. View

15.

Guha P, Morgan J, Mostoslavsky G, Rodrigues N, Boyd A . Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell. 2013; 12(4):407-12. DOI: 10.1016/j.stem.2013.01.006. View

16.

Lemonnier T, Blanchard S, Toli D, Roy E, Bigou S, Froissart R . Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. Hum Mol Genet. 2011; 20(18):3653-66. DOI: 10.1093/hmg/ddr285. View

17.

Passini M, Lee E, Heuer G, Wolfe J . Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci. 2002; 22(15):6437-46. PMC: 6758166. DOI: 20026665. View

18.

Simonato M, Bennett J, Boulis N, Castro M, Fink D, Goins W . Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013; 9(5):277-91. PMC: 3908892. DOI: 10.1038/nrneurol.2013.56. View

19.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

20.

Chaubey S, Wolfe J . Transplantation of CD15-enriched murine neural stem cells increases total engraftment and shifts differentiation toward the oligodendrocyte lineage. Stem Cells Transl Med. 2013; 2(6):444-54. PMC: 3673756. DOI: 10.5966/sctm.2012-0105. View